Navigation Links
More Research Points to Long-Term Ills With Bone Drugs
Date:5/21/2012

MONDAY, May 21 (HealthDay News) -- Adding more weight to concerns about possible long-term dangers of osteoporosis drugs, a new study finds that people who take the drugs, known as bisphosphonates, may be at increased risk for atypical fractures of the thigh bone (femur).

Osteoporosis is a bone-thinning disease that is common in older women. An atypical femoral fracture is an unusual type of break that often occurs spontaneously, without any major leg injury.

In the new study, Swiss researchers looked at 477 patients, aged 50 and older, who were hospitalized with a femoral fracture. Of those patients, 39 had atypical fractures and 438 had a classic fracture (a more common fracture with a typical pattern).

These groups were compared with 200 people without femoral fractures. The findings were published online May 21 in the journal Archives of Internal Medicine.

The investigators found that 82 percent of the patients with atypical fractures had been treated with bisphosphonates, such as Actonel or Fosamax, compared with about 6 percent of the patients with classic fractures.

But compared to patients without fractures, use of bisphosphonates was associated with a 47 percent reduction in the risk of a classic fracture.

The researchers compared duration of bisphosphonate treatment versus no treatment and found that the odds ratio for an atypical fracture versus a classic fracture was 35 to 1 for less than two years of treatment, 46 to 9 for two to five years of treatment, 117 to 1 for five to nine years of treatment, and 175 to 7 for more than nine years of treatment.

"In conclusion, we have demonstrated that the association between bisphosphonate treatment and the occurrence of atypical fractures of the femur is highly likely and that the duration of such treatment significantly correlates with augmented risk," Dr. Raphael Meier and colleagues from University Hospitals of Geneva and Faculty of Medicine in Geneva, concluded in a journal news release.

"However, the incidence rate was very low, and the absolute benefit to risk ratio of bisphosphonate use remains positive," the authors added.

While the study uncovered an association between bisphosphonate use and atypical fractures, it did not prove a cause-and-effect relationship.

In 2010, the U.S. Food and Drug Administration issued a warning about the possible risk of femur fractures from taking bisphosphonates over a long period of time.

More information

The National Osteoporosis Foundation has more about osteoporosis medicines.

-- Robert Preidt

SOURCE: Archives of Internal Medicine, news release, May 21, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kessler Foundation scientists present cognitive research findings at MS dual symposium
2. AGA presents cutting-edge research during DDW®
3. Research With Dogs Points to Early Test for Arthritis
4. Dartmouth researchers investigate the cognitive effects of athlete head impacts
5. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
6. Fox Chase researchers find no disparities in imaging before breast cancer surgery
7. More cutting-edge cancer research supported by industry
8. Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO
9. Researchers undertake radical new cancer survivorship study
10. Parents are happier than non-parents, new research suggests
11. Researchers make promising discovery in pursuit of effective lymphoma treatments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Research Points to Long-Term Ills With Bone Drugs
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
(Date:4/24/2017)... Nashville, TN (PRWEB) , ... April 24, 2017 , ... ... electrifying fans and transforming the quarterback position. The former overall number one pick in ... his professional football career. He holds the record for the most career rushing yards ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: